anti-SARS-CoV-2 Spike Protein S1 (RBD), mAb (rec.) (AB68-A09) (Fc Human)

CHF 330.00
In stock
AG-27B-6310-C05050 µgCHF 330.00
NEW
More Information
Product Details
Synonyms 2019-nCoV Spike Protein S1 (RBD); Spike Receptor Binding Domain
Product Type Recombinant Antibody
Properties
Clone AB68-A09
Isotype Human IgG1
Source/Host Produced without the use of animals. Purified from HEK 293 cell culture supernatant.
Immunogen/Antigen Recombinant SARS-CoV-2 S1 receptor binding protein (aa 319-591) containing a C-terminal human Fc-tag.
Application

ELISA
Immunocytochemistry
Western Blot (non-reducing)

Crossreactivity Virus
Specificity

Recognizes the SARS-CoV-2 S1 (Receptor-binding domain) of different mutant variants, including Omicron. Does not cross-react with HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-HKU1, MERS-CoV or SARS-CoV.

Purity ≥95% (SDS-PAGE)
Purity Detail Protein A purified from animal component-free supernatant.
Concentration 1 mg/ml
Formulation Liquid. In PBS.
Isotype Negative Control

Human IgG1 Isotype Control

Other Product Data

This is an antibody developed by antibody phage display technology using a human naive antibody gene library. For this antibody both the heavy and light chains are cloned and expressed, generating full-length antibodies. It has a Y-shaped structure of a common full-length IgG, consisting of 4 polypeptide, 2 heavy-chains and 2 light-chains.

Accession Number P0DTC2 (aa 319-541)
Declaration Manufactured by Abcalis
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Please handle under sterile conditions to avoid contamination.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Stable for at least 3 months after receipt when stored at +4°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF

Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome β-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S protein plays a key role in viral infection and pathogenesis. The S1 subunit contains the N-terminal domain (NTD) and a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells, whereas S2 harbors heptad repeat 1 (HR1) and HR2. The RBD domain first binds its receptor to form an RBD/ACE2 complex. This triggers conformational changes in the S protein, leading to membrane fusion mediated via HR1 and HR2 and consequently in viral entry into target cells. Antibodies targeting various regions of S protein have different mechanisms in inhibiting SARS-CoV-2 infection. For example, NTD-targeting antibodies bind the NTD to form an NTD/mAb complex, thereby preventing conformational changes in the S protein and blocking membrane fusion and viral entry. RBD-targeting antibodies form RBD/mAb or RBD/Nb complexes that inhibit binding of the RBD to ACE2, thereby preventing entry of SARS-CoV-2 into target cells.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.